REDWOOD CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)--PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections. PaxVax will license intellectual property and work together with Deborah Spector, Ph.D., distinguished professor in the UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences and the university’s Department of Cellular and Molecular Medicine to select the optimal vaccine combination and take this vaccine candidate into clinical trials. Financial terms of the collaboration were not disclosed.
Help employers find you! Check out all the jobs and post your resume.
